PF-Atlas › Clinical Trials › NCT01641393
Safety and Efficacy Study of 2 Pancreatic Enzymes for Treatment of Exocrine Pancreatic Insufficiency in Cystic Fibrosis.
EUR-1008 25,000 Units · Phase 3
Registry ID
NCT01641393
Phase
Phase 3
Status
Completed
Drug / intervention
EUR-1008 25,000 Units
Sponsor
Forest Laboratories
Start
2012-06
About this trial
EUR-1008 25,000 Units is evaluated in NCT01641393, a Phase 3 idiopathic pulmonary fibrosis study sponsored by Forest Laboratories. Current status: Completed.
Explore related
Medical disclaimer. This page summarizes public trial data for NCT01641393 for information only. It is not medical advice, an endorsement, or an offer to enroll. Confirm details on ClinicalTrials.gov and with a qualified physician.